Guildford, United Kingdom
NCT Number: NCT01531920
A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel
A Phase 1 study in healthy subjects to determine the safety, tolerability, psychomotor function, and cognitive effects of perampanel when administered alone and with alcohol.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–55 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion:
- Healthy male and female subjects
- Females agreed to use two medically acceptable methods of contraception, unless they were surgically sterile
- Aged 18-55 yrs, inclusive
- Achieved a Continuous Tracking Test (CTT )score increase of >1.5 pixels from pre-alcohol when dosed with alcohol during the Screening Period (Day minus 8 plus/minus 2 days)
- Had a current driving license and drove regularly (e.g., more than 1000 miles a year (Part B only)
Exclusion:
- Any history of significant alcohol abuse or psychiatric disease, requiring inpatient admission or prolonged treatment with psychotropic medication
- Unable to follow the instructions for the psychometric testing
- Intolerant to the driving simulator (Part B only)
- Unable to adhere to long periods of confinement (subjects who could not follow the instructions of the protocol, including the meals)
- Use of prescription drugs or over-the-counter (OTC) medications within 2 weeks prior to Screening (unless drug had a long half life [i.e., 5 x t 1/2>2 weeks]) with the exception of paracetamol (up to 4 g/day), which was allowed up to 12 hours prior to dosing
- Had taken any inhibitor of CYP450 within 2 weeks prior to the first dosing (e.g., grapefruit, grapefruit juice, grapefruit-containing beverages, or Seville orange products)
- Had taken St John's Wort or other dietary aids known to induce CYP3A4 within 4 weeks prior to dosing
Treatment and study plan
alcohol + placebo
DrugPart A alcohol + placebo
alcohol + perampanel
DrugPart A: alcohol + perampanel
perampanel + alcohol
DrugPart B: perampanel + alcohol
placebo + alcohol
DrugPart B: placebo + alcohol
Primary outcomes
-
Part A: Changes on Psychomotor Performance (Continuous Tracking Test [CTT]), due to perampanel and alcohol combined and perampanel alone
Time frame: baseline to Part A Day 1
-
Part B: Changes on Psychomotor Performance (Continuous Tracking Test [CTT]) due to perampanel and alcohol combined and perampanel alone
Time frame: baseline to Part B Day 62
-
Part B:Changes in Cognitive Function due to perampanel and alcohol combined and perampanel alone
Time frame: baseline to Part B Day 62
-
Part B: Part B: Changes in driving performance (simulated) due to perampanel and alcohol combined and perampanel alone
Time frame: Part B Day 34
Secondary outcomes
-
Part A: Incidence of AEs when perampanel is administered in combination with alcohol
Time frame: baseline to Part A Day 29
-
Part B: Incidence of AEs when perampanel is administered in combination with alcohol
Time frame: baseline to Part B Day 62
Sponsors and collaborators
Lead sponsor
Eisai Limited
Industry
Registry information
Official study title
A Phase 1 Study in Healthy Subjects to Determine the Safety, Tolerability, Psychomotor Function and Cognitive Effects of Perampanel When Administered With Alcohol
Important dates
- Study start
- 2010
- Primary completion
- 2011
- Study completion
- 2011
- First posted
- Feb 13, 2012
- Registry last updated
- Feb 13, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets
NCT06680531
Central Nervous System, Dyssomnias
Guangzhou, China
View Trial DetailsRapid Declarative Neocortical Declarative Learning in Aging and Memory Diseases (ANéRAVIMM)
NCT04846764
Central Nervous System, Neurological Diseases
Rennes, France
View Trial DetailsContrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions
NCT03268239
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Paris, France
View Trial DetailsEffects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
NCT02652260
Central Nervous System, HIV-1
View Trial Details